TILRAY BRANDS INC (TLRY.CA) Stock Fundamental Analysis
Canada - TSX:TLRY - US88688T1007 - Common Stock
1.43 CAD
-0.09 (-5.92%)
Taking everything into account, TLRY scores 2 out of 10 in our fundamental rating. TLRY was compared to 32 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of TLRY have multiple concerns. TLRY is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TLRY has reported negative net income.
TLRY had a negative operating cash flow in the past year.
TLRY had negative earnings in each of the past 5 years.
TLRY had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
TLRY's Return On Assets of -105.42% is on the low side compared to the rest of the industry. TLRY is outperformed by 84.38% of its industry peers.
Looking at the Return On Equity, with a value of -144.68%, TLRY is doing worse than 78.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.42% | ||
| ROE | -144.68% | ||
| ROIC | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of TLRY (29.29%) is comparable to the rest of the industry.
TLRY's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TLRY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TLRY has more shares outstanding
TLRY has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TLRY has a worse debt to assets ratio.
2.2 Solvency
TLRY has an Altman-Z score of -1.51. This is a bad value and indicates that TLRY is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TLRY (-1.51) is worse than 62.50% of its industry peers.
TLRY has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
TLRY has a Debt to Equity ratio (0.19) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.51 |
ROIC/WACCN/A
WACC7.76%
2.3 Liquidity
TLRY has a Current Ratio of 2.46. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.46, TLRY perfoms like the industry average, outperforming 59.38% of the companies in the same industry.
A Quick Ratio of 1.49 indicates that TLRY should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.49, TLRY is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.46 | ||
| Quick Ratio | 1.49 |
3. Growth
3.1 Past
TLRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -648.00%.
TLRY shows a small growth in Revenue. In the last year, the Revenue has grown by 4.10%.
The Revenue has been growing by 37.52% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
3.2 Future
TLRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.44% yearly.
The Revenue is expected to grow by 4.31% on average over the next years.
EPS Next Y97.21%
EPS Next 2Y40.83%
EPS Next 3Y26.48%
EPS Next 5Y15.44%
Revenue Next Year3.68%
Revenue Next 2Y4.08%
Revenue Next 3Y4.04%
Revenue Next 5Y4.31%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TLRY is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 47.58 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TLRY's earnings are expected to grow with 26.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.83%
EPS Next 3Y26.48%
5. Dividend
5.1 Amount
TLRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TLRY (11/17/2025, 7:00:00 PM)
1.43
-0.09 (-5.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners9.86%
Inst Owner ChangeN/A
Ins Owners0.36%
Ins Owner ChangeN/A
Market Cap1.61B
Revenue(TTM)821.31M
Net Income(TTM)-2.19B
Analysts71.25
Price Target2.65 (85.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2749.13%
Min EPS beat(2)-5362.97%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-1413.07%
Min EPS beat(4)-5362.97%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-730.51%
EPS beat(12)1
Avg EPS beat(12)-762.79%
EPS beat(16)3
Avg EPS beat(16)-613.4%
Revenue beat(2)0
Avg Revenue beat(2)-10.25%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-7.23%
Revenue beat(4)0
Avg Revenue beat(4)-8.93%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-4.66%
Revenue beat(8)0
Avg Revenue beat(8)-5.77%
Revenue beat(12)1
Avg Revenue beat(12)-3.93%
Revenue beat(16)1
Avg Revenue beat(16)-4.24%
PT rev (1m)83.12%
PT rev (3m)106.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.71%
EPS NY rev (1m)61.11%
EPS NY rev (3m)77.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)-1.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.76 | ||
| P/tB | 1.55 | ||
| EV/EBITDA | 47.58 |
EPS(TTM)-2.1
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS1.03
BVpS1.89
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.42% | ||
| ROE | -144.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.29% | ||
| FCFM | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
F-Score4
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 11.15 | ||
| Cap/Depr | 24.66% | ||
| Cap/Sales | 4.01% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.46 | ||
| Quick Ratio | 1.49 | ||
| Altman-Z | -1.51 |
F-Score4
WACC7.76%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.01%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y97.21%
EPS Next 2Y40.83%
EPS Next 3Y26.48%
EPS Next 5Y15.44%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
Revenue Next Year3.68%
Revenue Next 2Y4.08%
Revenue Next 3Y4.04%
Revenue Next 5Y4.31%
EBIT growth 1Y-11.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.7%
EBIT Next 3Y29.32%
EBIT Next 5Y17.43%
FCF growth 1Y-111.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-206.1%
OCF growth 3YN/A
OCF growth 5YN/A
TILRAY BRANDS INC / TLRY.CA FAQ
Can you provide the ChartMill fundamental rating for TILRAY BRANDS INC?
ChartMill assigns a fundamental rating of 2 / 10 to TLRY.CA.
What is the valuation status of TILRAY BRANDS INC (TLRY.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to TILRAY BRANDS INC (TLRY.CA). This can be considered as Overvalued.
How profitable is TILRAY BRANDS INC (TLRY.CA) stock?
TILRAY BRANDS INC (TLRY.CA) has a profitability rating of 1 / 10.
How financially healthy is TILRAY BRANDS INC?
The financial health rating of TILRAY BRANDS INC (TLRY.CA) is 3 / 10.